$23.18
-2.25-8.85%
最終更新: Sep 24, 11:37 AM
Benzinga
Benzinga
Benzinga
木曜日, 9 24
ACADIA Pharmaceuticals Inc
ACADNASDAQ
ACADIA Pharmaceuticals Earnings & Forecasts
ACADIA Pharmaceuticals (ACAD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ACADIA Pharmaceuticals Guidance
ACADIA Pharmaceuticals (ACAD) は、8 4, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$1.24B - $1.3Bの範囲と予想しています。
以前のガイダンスと比較して、ACADIA Pharmaceuticalsは売上高予測を以前の範囲である引き上げから$1.22B - $1.28Bに引き上げました。
ACADIA Pharmaceuticalsは、15から11 2, 2022の間に8 4, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.04 | $0.07 | $0.13 | $0.14 |
| Actual | $0.18 | $0.02 | $0.14 | $0.26 |
| Surprise | +350.0% | -71.4% | +7.69% | +85.7% |
| Revenue | ||||
| Estimate | $295.2M | $280.6M | $292.5M | $275.4M |
| Actual | $308.0M | $268.1M | $284.0M | $278.6M |
| Surprise | +4.31% | -4.48% | -2.92% | +1.19% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.19 | $0.22 | $0.18 | $0.20 |
| Revenue | ||||
| Consensus | $332.4M | $363.4M | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved